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Background: Post-procedural anticoagulation (AC) after primary PCI in STEMI is regularly administered for a number of specific indications, as well 
as for routine prophylaxis; however, the risks and benefits associated with such treatment have not been well established.
methods: 3,343 STEMI patients from the HORIZONS-AMI trial in whom PCI was performed were grouped according to whether or not they received any 
form of post-PCI AC. Rates of adverse outcomes were assessed with propensity-adjusted multivariable analysis at in-hospital and 30-day time points.
results: 1,282 (38.3%) patients received post-procedural AC with some patients receiving more than one agent, including unfractionated heparin 
(n=404), low-molecular weight heparin (n=915) and bivalirudin (n=219). Of those that received AC, 813 (24.3%) received AC for routine prophylaxis 
and 469 (14.0%) received AC for a number of therapeutic indications (e.g. mural thrombus, established DVT or IABP). By multivariable analysis, use 
of post-procedural AC compared to no AC was an independent predictor of in-hospital reinfarction, stent thrombosis and major bleeding, and of 
30-day cardiac and all-cause death (Table).
conclusion: In this large-scale study, the administration of post-procedural AC after primary PCI for STEMI was an independent predictor of early 
death, reinfarction, stent thrombosis and major bleeding. Further studies to determine which patients benefit from post-procedural AC are warranted.
Table. In-Hospital and 30-Day Outcomes for Post-procedural and No Anticoagulation Groups
In-Hospital Outcomes
Post-procedural Anticoagulation (N=1282) No Post-procedural Anticoagulation (N=2061) Adjusted Odds Ratio Adjusted p-value
All-cause Death 2.6% (33/1282) 1.9% (40/2061) 1.41 [0.80, 2.49] 0.24
Cardiac Death 2.3% (30/1282) 1.7% (36/2061) 1.49 [0.82, 2.70] 0.19
Reinfarction 2.0% (26/1282) 0.8% (17/2061) 2.14 [1.10, 4.16] 0.03
Stent thrombosis (def/prob) 2.4% (29/1206) 1.3% (25/1994) 2.28 [1.26, 4.11] 0.006
Stroke 0.6% (8/1282) 0.3% (6/2061) 1.17 [0.34, 3.97] 0.80
Non-CABG Major Bleeding 9.2% (118/1282) 5.5% (113/2061) 1.62 [1.21, 2.17] 0.001
MACE 5.9% (76/1282) 3.5% (72/2061) 1.73 [1.18, 2.56] 0.005
NACE 13.0% (167/1282) 8.1% (167/2061) 1.61 [1.25, 2.07] 0.0002
30-Day Outcomes
Post-procedural Anticoagulation (N=1282) No Post-procedural Anticoagulation (N=2061) Adjusted Hazard Ratio Adjusted p-value
All-cause Death 3.2% (41) 2.0% (41) 1.77 [1.04, 3.01] 0.04
Cardiac Death 3.0% (38) 1.9% (39) 1.77 [1.02, 3.09] 0.04
Reinfarction 2.5% (32) 1.6% (32) 1.51 [0.88, 2.60] 0.13
Stent thrombosis (def/prob) 3.2% (38) 1.9% (38) 1.71 [1.05, 2.77] 0.03
Stroke 0.6% (8) 0.5% (10) 0.74 [0.24, 2.29] 0.61
Non-CABG Major Bleeding 9.8% (125) 6.0% (122) 1.55 [1.18, 2.03] 0.002
MACE 7.1% (91) 4.4% (90) 1.68 [1.21, 2.33] 0.007
NACE 14.7% (188) 9.1% (188) 1.53 [1.22, 1.92] 0.0002
MACE=Major Adverse Cardiovascular Events (death, myocardial infarction unplanned revascularization for ischemia, stroke); NACE=Net Adverse Clinical Events (MACE or major 
bleeding).
